Tang Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Tang Capital Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-16,000	Closed	-$5.17M	–	106
2023 Q4	$5.17M	Sell	16,000 -8,000	-33%	-$2.51M	0.48%	53
2023 Q3	$8.6M	Buy	24,000 +8,000	+50%	+$3.09M	1.21%	26
2023 Q2	$6.07M	Hold	16,000	–	–	0.89%	33
2023 Q1	$7.66M	Sell	16,000 -5,000	-24%	-$2.34M	1.14%	30
2022 Q4	$8.83M	Sell	21,000 -43,000	-67%	-$17.4M	1.28%	24
2022 Q3	$26.7M	Buy	64,000 +5,000	+8%	+$2.49M	3.27%	8
2022 Q2	$29.2M	Buy	59,000 +19,000	+48%	+$9.9M	4.43%	8
2022 Q1	$22.5M	Buy	+40,000	New	+$24.1M	4.51%	5
2020 Q4	–	Sell	-40,000	Closed	-$20.6M	–	12
2020 Q3	$20.6M	Sell	40,000 -40,000	-50%	-$20.3M	3.73%	7
2020 Q2	$36.1M	Hold	80,000	–	–	3.51%	7
2020 Q1	$28M	Buy	+80,000	New	+$29.4M	3.94%	7

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Tang Capital Management's BIO Position: Q1 2024 in Review

Tang Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2024, closing a stake of 16,000 shares — an estimated $5.17M sold.

Tang Capital Management first reported a position in BIO in Q1 2020 and held it in 11 quarters. The position peaked at $36.1M in Q2 2020. 466 funds tracked by Wall St. Rank hold BIO as of Q1 2024.

Tang Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q1 2024 after selling out during the quarter.
Tang Capital Management sold 16,000 Bio-Rad Laboratories Class A shares in Q1 2024, an estimated $5.17M.
Tang Capital Management first reported a position in Bio-Rad Laboratories Class A in Q1 2020 and held it in 11 quarters.
Tang Capital Management's Bio-Rad Laboratories Class A position peaked at $36.1M in Q2 2020.
466 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2024.

Based on Tang Capital Management's 13F filing for Q1 2024, filed 15 May 2024.